8-K Announcements
6Material company update
Feb 24, 2026·SEC
Material company update
Dec 8, 2025·SEC
Material company update
Dec 2, 2025·SEC
Evolent Health, Inc.(EVH)Earnings, Financials & Key Ratios
EVH•NYSE
$3.83
$428M mkt cap·Price updated May 6, 2026
AboutEvolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.Show more
- Revenue$1.88B-26.6%
- EBITDA$111M+34.8%
- Net Income-$535M-767.4%
- EPS (Diluted)-5.07-525.9%
- Gross Margin15.09%+4.9%
- EBITDA Margin5.94%+83.5%
- Operating Margin-0.24%+85.1%
- Net Margin-28.49%-1081.1%
- ROE-75.47%-1167.0%
- ROIC-0.23%+88.0%
- Debt/Equity2.38+234.4%
- Interest Coverage-8.30-435.7%
EVH Key Insights
Evolent Health, Inc. (EVH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 15.2%
- ✓Healthy dividend yield of 2.5%
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗High debt to equity ratio of 2.4x
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
EVH Price & Volume
Evolent Health, Inc. (EVH) stock price & volume — 10-year historical chart
Loading chart...
EVH Growth Metrics
Evolent Health, Inc. (EVH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years34.49%
5 Years15.2%
3 Years11.54%
TTM-26.56%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-767.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-521.55%
Return on Capital
10 Years-8.74%
5 Years-2.08%
3 Years-2.19%
Last Year-0.27%
EVH Recent Earnings
Evolent Health, Inc. (EVH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 24, 2026EPS
$0.08
Est $0.06
+33.3%
Revenue
$469M
Est $469M
+0.0%
Q4 2025
Nov 6, 2025EPS
$0.05
Est $0.10
-50.0%
Revenue
$480M
Est $468M
+2.4%
Q3 2025
Aug 7, 2025EPS
$0.10
Est $0.09
-211.1%
Revenue
$444M
Est $532M
-16.5%
Q2 2025
May 8, 2025EPS
$0.06
Est $0.09
-33.3%
Revenue
$484M
Est $460M
+5.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 24, 2026 | $0.08vs $0.06+33.3% | $469Mvs $469M+0.0% |
| Q4 2025 | Nov 6, 2025 | $0.05vs $0.10-50.0% | $480Mvs $468M+2.4% |
| Q3 2025 | Aug 7, 2025 | $0.10vs $0.09-211.1% | $444Mvs $532M-16.5% |
| Q2 2025 | May 8, 2025 | $0.06vs $0.09-33.3% | $484Mvs $460M+5.1% |
Based on last 12 quarters of dataView full earnings history →
EVH Peer Comparison
Evolent Health, Inc. (EVH) competitors in Care Delivery Networks and Value-Based Care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PINC | 2.34B | 28.26 | 128.45 | -10.86% | -2.42% | -1.59% | 0.18 | |
 ALHC | 3.71B | 18.14 | -4902.70 | 46.06% | 0.47% | 11.5% | 1.89 | |
 HQY | 7.08B | 83.25 | 33.84 | 9.47% | 16.38% | 10.11% | 0.02 | |
 TDOC | 1.23B | 6.80 | -5.96 | -1.54% | -6.81% | -12.37% | 0.75 | |
 OSCR | 5.14B | 19.84 | -11.74 | 27.5% | -0.3% | -3.26% | 0.44 | |
 CLOV | 1.37B | 2.68 | -15.76 | 40.34% | -2.58% | -17.08% | ||
 HIMS | 6.94B | 26.88 | 52.71 | 59% | 5.47% | 23.73% | 2.07 | |
 DOCS | 5.17B | 25.69 | 23.14 | 19.98% | 37.54% | 24.45% | 0.01 |
Compare EVH vs Peers
Evolent Health, Inc. (EVH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EVH Income Statement
Evolent Health, Inc. (EVH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 434.95M | 627.06M | 687.12M | 924.64M | 907.96M | 1.35B | 1.96B | 2.55B | 1.88B |
| Revenue Growth % | 71.11% | 44.17% | 9.58% | 34.57% | -1.8% | 48.91% | 45.26% | 30.09% | -26.56% |
| Cost of Goods Sold | 269.35M | 327.82M | 513.03M | 696.58M | 657.55M | 1.04B | 1.5B | 2.19B | 1.59B |
| COGS % of Revenue | 61.93% | 52.28% | 74.66% | 75.34% | 72.42% | 76.58% | 76.55% | 85.62% | 84.91% |
| Gross Profit | 165.6M▲ 0% | 299.24M▲ 80.7% | 174.09M▼ 41.8% | 228.06M▲ 31.0% | 250.41M▲ 9.8% | 316.58M▲ 26.4% | 460.47M▲ 45.4% | 367.35M▼ 20.2% | 283.03M▼ 23.0% |
| Gross Margin % | 38.07% | 47.72% | 25.34% | 24.66% | 27.58% | 23.42% | 23.45% | 14.38% | 15.09% |
| Gross Profit Growth % | 67.25% | 80.7% | -41.82% | 31% | 9.8% | 26.43% | 45.45% | -20.22% | -22.95% |
| Operating Expenses | 238.04M | 350.82M | 482.97M | 490.9M | 292.82M | 312.94M | 531.68M | 407.84M | 287.47M |
| OpEx % of Revenue | 54.73% | 55.95% | 70.29% | 53.09% | 32.25% | 23.15% | 27.07% | 15.96% | 15.32% |
| Selling, General & Admin | 205.67M | 306.31M | 236.45M | 210.41M | 219.5M | 269.27M | 358.11M | 263.05M | 303.87M |
| SG&A % of Revenue | 47.29% | 48.85% | 34.41% | 22.76% | 24.18% | 19.92% | 18.23% | 10.3% | 16.2% |
| Research & Development | 17.2M | 18.2M | 0 | 0 | 0 | 27M | 0 | 0 | 0 |
| R&D % of Revenue | 3.95% | 2.9% | - | - | - | 2% | - | - | - |
| Other Operating Expenses | 171K | 109K | 246.53M | 280.49M | 73.32M | 16.67M | 173.57M | 144.79M | -16.4M |
| Operating Income | -72.84M▲ 0% | -47.48M▲ 34.8% | -308.88M▼ 550.6% | -262.85M▲ 14.9% | -42.41M▲ 83.9% | 3.64M▲ 108.6% | -71.21M▼ 2055.3% | -40.48M▲ 43.1% | -4.43M▲ 89.0% |
| Operating Margin % | -16.75% | -7.57% | -44.95% | -28.43% | -4.67% | 0.27% | -3.63% | -1.58% | -0.24% |
| Operating Income Growth % | 69.32% | 34.82% | -550.56% | 14.9% | 83.86% | 108.59% | -2055.27% | 43.15% | 89.05% |
| EBITDA | -40.47M | -2.96M | -247.97M | -201.37M | 17.63M | 93.89M | 52.2M | 82.68M | 111.42M |
| EBITDA Margin % | -9.3% | -0.47% | -36.09% | -21.78% | 1.94% | 6.94% | 2.66% | 3.24% | 5.94% |
| EBITDA Growth % | 81.62% | 92.67% | -8263.31% | 18.79% | 108.75% | 432.7% | -44.4% | 58.38% | 34.75% |
| D&A (Non-Cash Add-back) | 32.37M | 44.52M | 60.91M | 61.48M | 60.04M | 90.25M | 123.42M | 123.17M | 115.85M |
| EBIT | -72.77M | -48.67M | -315.43M | -302.21M | -4.38M | -46.51M | -148.2M | -38.31M | -477.17M |
| Net Interest Income | -1.98M | -2.04M | -11.15M | -25.69M | -25.02M | -14.2M | -48.95M | -19.18M | -53.28M |
| Interest Income | 1.66M | 3.44M | 3.41M | 2.63M | 407K | 1.37M | 5.26M | 5.54M | 4.19M |
| Interest Expense | 3.64M | 5.48M | 14.55M | 28.32M | 25.43M | 15.57M | 54.2M | 24.72M | 57.47M |
| Other Income/Expense | -3.56M | -6.67M | -21.1M | -67.69M | 12.61M | -65.72M | -131.19M | -22.55M | -530.2M |
| Pretax Income | -76.4M▲ 0% | -54.15M▲ 29.1% | -329.99M▼ 509.4% | -330.54M▼ 0.2% | -29.8M▲ 91.0% | -62.08M▼ 108.3% | -202.41M▼ 226.1% | -63.04M▲ 68.9% | -534.64M▼ 748.1% |
| Pretax Margin % | -17.57% | -8.64% | -48.02% | -35.75% | -3.28% | -4.59% | -10.31% | -2.47% | -28.5% |
| Income Tax | -6.64M | 40K | -22.8M | -2.37M | 483K | -43.38M | -89.36M | -1.41M | -126K |
| Effective Tax Rate % | 8.69% | -0.07% | 6.91% | 0.72% | -1.62% | 69.87% | 44.15% | 2.24% | 0.02% |
| Net Income | -60.66M▲ 0% | -52.66M▲ 13.2% | -301.97M▼ 473.5% | -334.25M▼ 10.7% | -37.6M▲ 88.8% | -19.16M▲ 49.0% | -113.04M▼ 489.9% | -61.62M▲ 45.5% | -534.51M▼ 767.4% |
| Net Margin % | -13.95% | -8.4% | -43.95% | -36.15% | -4.14% | -1.42% | -5.76% | -2.41% | -28.49% |
| Net Income Growth % | 62.02% | 13.2% | -473.46% | -10.69% | 88.75% | 49.03% | -489.86% | 45.49% | -767.39% |
| Net Income (Continuing) | -69.77M | -54.19M | -307.19M | -328.17M | -30.28M | -18.7M | -113.04M | -61.62M | -534.51M |
| Discontinued Operations | 0 | 0 | 1.61M | -6.07M | -7.32M | -463K | 0 | 0 | 0 |
| Minority Interest | 35.43M | 45.53M | 6.69M | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.94▲ 0% | -0.68▲ 27.7% | -3.71▼ 445.6% | -3.94▼ 6.2% | -0.36▲ 90.9% | -0.20▲ 44.4% | -1.28▼ 540.0% | -0.81▲ 36.7% | -5.07▼ 525.9% |
| EPS Growth % | 73.52% | 27.66% | -445.59% | -6.2% | 90.86% | 44.44% | -540% | 36.72% | -525.93% |
| EPS (Basic) | -0.94 | -0.68 | -3.71 | -3.94 | -0.36 | -0.20 | -1.28 | -0.81 | -5.07 |
| Diluted Shares Outstanding | 64.35M | 77.34M | 82.36M | 84.93M | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
| Basic Shares Outstanding | 64.35M | 77.34M | 82.36M | 84.93M | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
EVH Balance Sheet
Evolent Health, Inc. (EVH) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 378.18M | 487.97M | 228.8M | 547.65M | 523.96M | 478.05M | 683.67M | 607.12M | 506.37M |
| Cash & Short-Term Investments | 238.43M | 228.32M | 102.81M | 333.38M | 266.28M | 188.2M | 192.82M | 163.5M | 151.86M |
| Cash Only | 238.43M | 228.32M | 101.01M | 333.38M | 266.28M | 188.2M | 192.82M | 104.2M | 151.86M |
| Short-Term Investments | 0 | 0 | 1.81M | 0 | 0 | 0 | 0 | 59.3M | 0 |
| Accounts Receivable | 68.95M | 82.31M | 77.42M | 124.39M | 130.6M | 254.68M | 446.75M | 414.68M | 323.4M |
| Days Sales Outstanding | 57.86 | 47.91 | 41.12 | 49.1 | 52.5 | 68.76 | 83.03 | 59.25 | 62.91 |
| Inventory | -3.26M | 78.51M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 87.42 | - | - | - | - | - | - | - |
| Other Current Assets | 62.4M | 154.72M | 20.08M | 89.88M | 75.69M | 35.17M | 44.1M | 28.94M | 31.12M |
| Total Non-Current Assets | 869.45M | 1.11B | 1.27B | 926.79M | 895.5M | 1.34B | 2B | 1.94B | 1.39B |
| Property, Plant & Equipment | 50.92M | 73.63M | 157.33M | 144.04M | 131.57M | 136.9M | 90.18M | 79.28M | 85.16M |
| Fixed Asset Turnover | 8.54x | 8.52x | 4.37x | 6.42x | 6.90x | 9.88x | 21.78x | 32.22x | 22.03x |
| Goodwill | 628.19M | 768.12M | 572.06M | 349.03M | 426.3M | 722.77M | 1.12B | 1.14B | 694.48M |
| Intangible Assets | 241.26M | 335.04M | 308.46M | 264.99M | 279.78M | 442.78M | 752.01M | 680.16M | 584.94M |
| Long-Term Investments | 1.53M | 10.01M | 139.37M | 17.71M | 5.46M | 4.47M | 4.89M | 8.59M | 8.97M |
| Other Non-Current Assets | 3.29M | 6.11M | 91.99M | 48.28M | 52.39M | 32.3M | 33.01M | 31.95M | 19.32M |
| Total Assets | 1.31B▲ 0% | 1.72B▲ 31.2% | 1.5B▼ 13.0% | 1.47B▼ 1.6% | 1.42B▼ 3.7% | 1.82B▲ 28.0% | 2.68B▲ 47.5% | 2.54B▼ 5.1% | 1.9B▼ 25.4% |
| Asset Turnover | 0.33x | 0.36x | 0.46x | 0.63x | 0.64x | 0.74x | 0.73x | 1.00x | 0.99x |
| Asset Growth % | 9.41% | 31.2% | -13.02% | -1.57% | -3.73% | 28.03% | 47.49% | -5.07% | -25.36% |
| Total Current Liabilities | 132.7M | 146.76M | 192.77M | 403.29M | 445.49M | 433.44M | 674.24M | 715.5M | 385.26M |
| Accounts Payable | 42.93M | 146.76M | 37.49M | 31.98M | 96.08M | 57.17M | 48.25M | 96.03M | 59.78M |
| Days Payables Outstanding | 58.17 | 163.4 | 26.67 | 16.75 | 53.34 | 20.15 | 11.71 | 16.02 | 13.69 |
| Short-Term Debt | 0 | 0 | 0 | 33.91M | 0 | 0 | 0 | 171.47M | 15.34M |
| Deferred Revenue (Current) | 24.81M | 20.58M | 19.83M | 10.19M | 11.94M | 5.76M | 5.98M | 2.51M | 1.2M |
| Other Current Liabilities | 29.57M | 76.55M | 95.84M | 280.06M | 223.16M | 252.19M | 460.43M | 352.42M | 308.94M |
| Current Ratio | 2.85x | 3.32x | 1.19x | 1.36x | 1.18x | 1.10x | 1.01x | 0.85x | 1.31x |
| Quick Ratio | 2.87x | 2.79x | 1.19x | 1.36x | 1.18x | 1.10x | 1.01x | 0.85x | 1.31x |
| Cash Conversion Cycle | - | -28.08 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 121.39M | 386.17M | 376.2M | 451.55M | 280.33M | 524.43M | 938.37M | 827.65M | 1.1B |
| Long-Term Debt | 121.39M | 221.04M | 293.67M | 263.34M | 215.68M | 412.99M | 597.05M | 490.52M | 970.54M |
| Capital Lease Obligations | 0 | 0 | 68.86M | 62.53M | 57.72M | 56.01M | 38.01M | 24.97M | 3.82M |
| Deferred Tax Liabilities | 2.44M | 25.44M | 1.94M | 103.42M | 1.4M | 50.69M | 121.24M | 119M | 7.51M |
| Other Non-Current Liabilities | 9.86M | 17.09M | 11.73M | 18.66M | 5.53M | 4.74M | 182.06M | 193.16M | 116.81M |
| Total Liabilities | 266.39M | 532.92M | 568.97M | 854.84M | 725.83M | 957.88M | 1.61B | 1.54B | 1.48B |
| Total Debt | 121.39M | 221.04M | 368.79M | 359.78M | 280.47M | 476.12M | 644.8M | 713.67M | 989.7M |
| Net Debt | -117.04M | -7.28M | 267.79M | 26.41M | 14.19M | 287.92M | 451.97M | 609.47M | 837.84M |
| Debt / Equity | 0.12x | 0.19x | 0.40x | 0.58x | 0.40x | 0.55x | 0.60x | 0.71x | 2.38x |
| Debt / EBITDA | - | - | - | - | 15.91x | 5.07x | 12.35x | 8.63x | 8.88x |
| Net Debt / EBITDA | - | - | - | - | 0.80x | 3.07x | 8.66x | 7.37x | 7.52x |
| Interest Coverage | -20.01x | -8.87x | -21.67x | -10.67x | -0.17x | -2.99x | -2.73x | -1.55x | -8.30x |
| Total Equity | 1.05B▲ 0% | 1.19B▲ 13.7% | 929.05M▼ 21.9% | 619.6M▼ 33.3% | 693.63M▲ 11.9% | 859.42M▲ 23.9% | 1.07B▲ 24.2% | 1B▼ 6.2% | 415.19M▼ 58.5% |
| Equity Growth % | 14.71% | 13.67% | -21.89% | -33.31% | 11.95% | 23.9% | 24.24% | -6.22% | -58.53% |
| Book Value per Share | 16.26 | 15.38 | 11.28 | 7.30 | 8.06 | 9.17 | 9.60 | 8.73 | 3.64 |
| Total Shareholders' Equity | 1.01B | 1.14B | 922.36M | 619.6M | 693.63M | 859.42M | 1.07B | 1B | 415.19M |
| Common Stock | 774K | 823K | 846K | 859K | 908K | 1.01M | 1.15M | 1.17M | 1.18M |
| Retained Earnings | 85.95M | 50.01M | -251.96M | -589.18M | -626.78M | -606.15M | -719.19M | -780.82M | -1.32B |
| Treasury Stock | 0 | 0 | 0 | -21.12M | -21.12M | -21.12M | -21.12M | -21.12M | -61.43M |
| Accumulated OCI | -14.46M | -182K | -234K | -278K | -362K | -1.18M | -1.26M | -1.75M | -2.62M |
| Minority Interest | 35.43M | 45.53M | 6.69M | 0 | 0 | 0 | 0 | 0 | 0 |
EVH Cash Flow Statement
Evolent Health, Inc. (EVH) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -27.96M | -20.65M | -42.65M | -16.23M | 38.75M | -11.55M | 142.58M | 18.77M | 38.84M |
| Operating CF Margin % | -6.43% | -3.29% | -6.21% | -1.75% | 4.27% | -0.85% | 7.26% | 0.73% | 2.07% |
| Operating CF Growth % | 21.27% | 26.14% | -106.5% | 61.95% | 338.81% | -129.82% | 1334.16% | -86.84% | 107% |
| Net Income | -69.77M | -54.19M | -301.97M | -328.17M | -37.6M | -19.16M | -113.04M | -61.62M | -579.4M |
| Depreciation & Amortization | 32.37M | 44.52M | 66.64M | 60.84M | 60.04M | 67.19M | 123.42M | 125.61M | 122.64M |
| Stock-Based Compensation | 20.44M | 17.61M | 0 | 0 | 16.71M | 33.98M | 40.5M | 39.75M | 39.74M |
| Deferred Taxes | -7.27M | 44K | -23.12M | -1.13M | -526K | 342K | -31.27M | -2.82M | -2.98M |
| Other Non-Cash Items | 3.56M | 6.24M | 215.48M | 307.56M | 22.61M | 10.53M | 101.09M | 34.4M | 516.23M |
| Working Capital Changes | -7.28M | -34.87M | 331K | -55.32M | -22.49M | -104.44M | 21.89M | -116.56M | -57.38M |
| Change in Receivables | -11.26M | -24.5M | 6.33M | -47.02M | -24.76M | -102.98M | -164.69M | 32.06M | 73.7M |
| Change in Inventory | -1.83M | 644K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 5.56M | 7.6M | -5.48M | 3.55M | 7.25M | 13.16M | -6.72M | 4.25M | 6.64M |
| Cash from Investing | -12.27M | -160.38M | -181.63M | 261.07M | -15.79M | -259.12M | -415.54M | -62.93M | -233K |
| Capital Expenditures | -27.85M | -39.55M | -35.53M | -31.76M | -24.98M | -38.36M | -28.75M | -24.89M | -34.09M |
| CapEx % of Revenue | 6.4% | 6.31% | 5.17% | 3.43% | 2.75% | 2.84% | 1.46% | 0.97% | 1.82% |
| Acquisitions | -4.82M | -139.6M | -8.57M | -300K | 14.22M | 5.55M | 870K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -20M | 28.44M | -41M | 160.86M | -2.53M | -226.31M | -387.67M | -30.72M | 34.85M |
| Cash from Financing | 165.56M | 274.02M | -35.55M | -11.86M | -29.55M | 131.54M | 281.34M | -565K | -35.92M |
| Debt Issued (Net) | 0 | 167.18M | 62.65M | 13.46M | -37.69M | 219.74M | 183.29M | 58.58M | 65.06M |
| Equity Issued (Net) | 166.95M | 0 | 1.09M | 2.58M | 0 | -18.32M | 168M | 3.46M | -40M |
| Dividends Paid | 0 | 0 | 0 | -20M | -1.3M | 0 | -18.79M | -20.09M | -11.13M |
| Share Repurchases | 0 | -1.24M | 0 | 0 | 0 | -18.32M | 0 | 0 | -40M |
| Other Financing | -1.39M | 106.85M | -99.28M | -7.89M | 9.44M | -69.88M | -51.16M | -42.52M | -49.86M |
| Net Change in Cash | 125.33M▲ 0% | 92.96M▼ 25.8% | -262.44M▼ 382.3% | 212.99M▲ 181.2% | -6.64M▼ 103.1% | -139.78M▼ 2005.5% | 8.3M▲ 105.9% | -44.96M▼ 641.8% | 14.49M▲ 132.2% |
| Free Cash Flow | -55.81M▲ 0% | -60.2M▼ 7.9% | -78.18M▼ 29.9% | -45.7M▲ 41.5% | 13.76M▲ 130.1% | -49.91M▼ 462.6% | 113.84M▲ 328.1% | -6.13M▼ 105.4% | 4.75M▲ 177.6% |
| FCF Margin % | -12.83% | -9.6% | -11.38% | -4.94% | 1.52% | -3.69% | 5.8% | -0.24% | 0.25% |
| FCF Growth % | -9.35% | -7.88% | -29.86% | 41.55% | 130.12% | -462.64% | 328.07% | -105.38% | 177.59% |
| FCF per Share | -0.87 | -0.78 | -0.95 | -0.54 | 0.16 | -0.53 | 1.02 | -0.05 | 0.04 |
| FCF Conversion (FCF/Net Income) | 0.46x | 0.39x | 0.14x | 0.05x | -1.03x | 0.60x | -1.26x | -0.30x | -0.07x |
| Interest Paid | 0 | 0 | 0 | 0 | 7.11M | 6.27M | 53.59M | 20.21M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 551K | 1.4M | 4.89M | 1.39M | 0 |
EVH Key Ratios
Evolent Health, Inc. (EVH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -17.3% | -6.2% | -4.71% | -28.51% | -43.17% | -5.73% | -2.47% | -11.73% | -5.96% | -75.47% |
| Return on Invested Capital (ROIC) | -21.11% | -5.98% | -3.37% | -19.48% | -21.39% | -4.7% | 0.29% | -4.01% | -1.94% | -0.23% |
| Gross Margin | 38.95% | 38.07% | 47.72% | 25.34% | 24.66% | 27.58% | 23.42% | 23.45% | 14.38% | 15.09% |
| Net Margin | -62.84% | -13.95% | -8.4% | -43.95% | -36.15% | -4.14% | -1.42% | -5.76% | -2.41% | -28.49% |
| Debt / Equity | 0.13x | 0.12x | 0.19x | 0.40x | 0.58x | 0.40x | 0.55x | 0.60x | 0.71x | 2.38x |
| Interest Coverage | -328.20x | -20.01x | -8.87x | -21.67x | -10.67x | -0.17x | -2.99x | -2.73x | -1.55x | -8.30x |
| FCF Conversion | 0.22x | 0.46x | 0.39x | 0.14x | 0.05x | -1.03x | 0.60x | -1.26x | -0.30x | -0.07x |
| Revenue Growth | 162.38% | 71.11% | 44.17% | 9.58% | 34.57% | -1.8% | 48.91% | 45.26% | 30.09% | -26.56% |
EVH SEC Filings & Documents
Evolent Health, Inc. (EVH) SEC filings — annual & quarterly reports (10-K, 10-Q)
EVH Frequently Asked Questions
Evolent Health, Inc. (EVH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Evolent Health, Inc. (EVH) reported $1.88B in revenue for fiscal year 2025. This represents a 22381% increase from $8.3M in 2012.
Evolent Health, Inc. (EVH) saw revenue decline by 26.6% over the past year.
Evolent Health, Inc. (EVH) reported a net loss of $534.5M for fiscal year 2025.
Dividend & Returns
Yes, Evolent Health, Inc. (EVH) pays a dividend with a yield of 2.54%. This makes it attractive for income-focused investors.
Evolent Health, Inc. (EVH) has a return on equity (ROE) of -75.5%. Negative ROE indicates the company is unprofitable.
Evolent Health, Inc. (EVH) generated $4.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More EVH
Evolent Health, Inc. (EVH) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates